BTMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biote Corp (BTMD) is not a strong buy for a beginner, long-term investor at this time. The stock lacks positive momentum, has declining financial performance, and no significant trading signals or catalysts to suggest immediate upside potential. While insider buying is a positive indicator, the overall technical and financial outlook does not support a compelling entry point.
The stock shows bearish moving averages (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. RSI is neutral at 37.764, and MACD is slightly positive but contracting. Key support levels are at $2.034 and $1.991, with resistance at $2.175 and $2.218. The stock has a 60% chance of a small decline (-1.03%) in the next day and a modest gain (3.2%) over the next month.
Insiders are buying, with a 221.99% increase in buying activity over the last month. Analysts maintain a Buy rating, albeit with a lowered price target of $5.
There is no recent news or event-driven catalysts, and hedge funds are neutral.
In Q3 2025, revenue dropped to $47.96M (-6.67% YoY), net income fell to $8.19M (-23.49% YoY), and EPS declined to $0.22 (-33.33% YoY). However, gross margin improved slightly to 71.77% (+1.84% YoY).
Truist recently lowered the price target from $6 to $5 but maintained a Buy rating. Analysts find the affordable medicines theme attractive heading into 2026.
